In our study, we show that STAT3 inhibition has an additive effect when combined with the most frequently used chemotherapeutic drugs approved for bladder cancer suggesting that this combination might be applicable in patients with STAT3 mediated chemo resistance. Here, STAT3 is linked to urinary bladder cancer.